SCHEMBL4865457

SCHEMBL4865457

COc1cc(C2=NNC(=O)C2=CNc2ccccc2)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 4/20 0.41
HPGD P15428 4/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDR P35968 2/20 0.40
PDGFRB P09619 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
MET P08581 1/20 0.38
BRAF P15056 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
MAP3K11 Q16584 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865450 1.00 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EHPGDMAPT
SCHEMBL4859407 0.81 ALDH1A1 (0.45) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL4859398 0.81 ALDH1A1 (0.45) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL23192514 0.81 ALDH1A1 (0.57) ALDH1A1LMNAKDM4EMAPTMEN1
SCHEMBL17481601 0.81 ALDH1A1 (0.57) ALDH1A1LMNAKDM4EMAPTMEN1
SCHEMBL17481600 0.80 ALDH1A1 (0.51) ALDH1A1LMNAKDM4EHPGDMAPT
SCHEMBL14003588 0.75 ALDH1A1 (0.58) ALDH1A1LMNAKDM4EHPGDMAPT
SCHEMBL4858516 0.75 ALDH1A1 (0.58) ALDH1A1LMNAKDM4EHPGDMAPT
SCHEMBL4858521 0.75 ALDH1A1 (0.58) ALDH1A1LMNAKDM4EHPGDMAPT
SCHEMBL17481602 0.75 ALDH1A1 (0.55) ALDH1A1LMNAKDM4EHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A ALDH1A1 3536/4885LMNA 828/4885KDM4E 941/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A ALDH1A1 3536/4885LMNA 828/4885KDM4E 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.